Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan;66(1):7–30. doi: 10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Onc. 2018 Sep 1;4(9):1221–1227. doi: 10.1001/jamaoncol.2018.2128
   PubMed Web of Science ®Google Scholar
• Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021 Jan 20;9(1):3. doi: 10.3390/medsci9010003
   PubMedGoogle Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266–2275. doi: 10.1038/s41375-019-0435-7
   PubMed Web of Science ®Google Scholar
• Moreau P, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma who received ≥3 prior lines of therapy. Blood. 2021;138(Supplement 1):3057. doi: 10.1182/blood-2021-146188
   Google Scholar
• Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022 May;36(5):1371–1376. doi: 10.1038/s41375-022-01531-2
   PubMed Web of Science ®Google Scholar
• Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma-a promising key to therapy. J Clin Med. 2021 Sep 10;10(18):4088. doi: 10.3390/jcm10184088
   PubMed Web of Science ®Google Scholar
• Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821
   PubMed Web of Science ®Google Scholar
• Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. J Hematol Oncol. 2021 Jul 23;14(1):115. doi: 10.1186/s13045-021-01109-y
   PubMed Web of Science ®Google Scholar
• Lee L, Bounds D, Paterson J, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016 Sep;174(6):911–922. doi: 10.1111/bjh.14145
   PubMed Web of Science ®Google Scholar
• Eckhert E, Hewitt R, Liedtke M. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma. Immunotherapy. 2019 Jun;11(9):801–811. doi: 10.2217/imt-2018-0199
   PubMed Web of Science ®Google Scholar
• Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2018 Jan 4;131(1):30–38. doi: 10.1182/blood-2017-06-741058
   PubMed Web of Science ®Google Scholar
• Ghosh A, Mailankody S, Giralt SA, et al. CAR T cell therapy for multiple myeloma: where are we now and where are we headed? Leuk Lymphoma. 2018 Sep;59(9):2056–2067. doi: 10.1080/10428194.2017.1393668
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature. 2017 May 24;545(7655):423–431. doi: 10.1038/nature22395
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 Feb 25;384(8):705–716. doi: 10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726–1737. doi: 10.1056/NEJMoa1817226
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023 Mar 16;388(11):1002–1014. doi: 10.1056/NEJMoa2213614 Epub 2023 Feb 10.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Idecabtagene Vicleucel (ide-cel) versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): updated Analysis from KarMMa-3. Blood. 2023;142(Supplement 1):Abstr 1028. doi: 10.1182/blood-2023-178933
   Google Scholar
• Patel K, Rodriguez-Otero P, Manier S, et al. Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis. International myeloma society 20th annual meeting and exposition; #P-040. Clin Lymphoma Myeloma Leukemia. 2023;23(Supplement 2):S56–57. doi: 10.1016/S2152-2650(23)01658-0
   Google Scholar
• Manier S, Rodriguez-Otero P, Mateos MV, et al. Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy. International myeloma society 20th annual meeting and exposition; #P-031. Clin Lymphoma Myeloma Leukemia. 2023;23(Supplement 2):S50–51. doi: 10.1016/S2152-2650(23)01649-X
   Google Scholar
• Einsele H, Rodriguez-Otero P, Arnulf B, et al. Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy. International Myeloma Society 20th Annual Meeting And Exposition #P-008 Clinical Lymphoma Myeloma And Leukemia. 2023;23(Supplement_2):S37. doi: 10.1016/S2152-2650(23)01626-9
   Google Scholar
• Shah N, Alsina M, Siegel DS, et al. Initial results from a phase 1 clinical study of bb21217, a next-generation anti BCMA CAR T therapy. Blood. 2018;Suppl. 132(Supplement 1):488. doi: 10.1182/blood-2018-99-116953
   Google Scholar
• Raje NS, Shah N, Jannagath S, et al. Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-Targeted CAR T Cell Therapy bb21217 in patients with relapsed and refractory multiple myeloma. Blood. 2021;138(Supplement 1):548. doi: 10.1182/blood-2021-146518
   Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul 24;398(10297):314–324. doi: 10.1016/S0140-6736(21)00933-8 Erratum in: Lancet. 2021 Oct 2;398(10307):1216.
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023 Feb 20;41(6):1265–1274. doi: 10.1200/JCO.22.00842
   PubMed Web of Science ®Google Scholar
• Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. 2023 ASCO annual meeting. Abstract 8009. JCO. 2023;41(16_suppl):8009–8009. doi: 10.1200/JCO.2023.41.16_suppl.8009
   Web of Science ®Google Scholar
• Jagannath S, Martin T, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. International myeloma society 20th annual meeting and exposition; #P-275. Clin Lymphoma Myeloma Leukemia. 2023;23(Supplement 2):S187. doi: 10.1016/S2152-2650(23)01893-1
   Google Scholar
• Zhao WH, Wang BY, Chen LJ, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022 Jul 6;15(1):86. doi: 10.1186/s13045-022-01301-8
   PubMed Web of Science ®Google Scholar
• Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023 Jan 19;141(3):219–230. doi: 10.1182/blood.2022015526
   PubMed Web of Science ®Google Scholar
• Einsele H, Cohen AD, Delforge M, et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel, a BCMA-Directed CAR-T cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma After 1–3 Prior Lines of Therapy: CARTITUDE-2, Cohort A. Presented at the 2022 American society of clinical oncology annual meeting. Abstract #8020 [Poster]. J Clin Oncol. 2022;40(16):2022.
   Web of Science ®Google Scholar
• van de Donk N, Delforge M, Agha M, et al. Safety and efficacy of ciltacabtagene autoleucel, a chimeric antigen receptor t-cell therapy directed against B-cell maturation antigen in patients with multiple myeloma and early relapse after initial therapy: CARTITUDE-2 results S. B07. Hemasphere. 2022 Apr 5;6(Suppl):9–10. doi: 10.1097/01.HS9.0000829568.10814.bc
   Google Scholar
• van de Donk N, Agha ME, Cohen AD, et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B. JCO. 2022;40(16_suppl):8029–8029. doi: 10.1200/JCO.2022.40.16_suppl.8029
   Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Updated Results from CARTITUDE-1: Phase 1b/2Study of ciltacabtagene autoleucel, a B-Cell maturation antigen-directed chimeric antigen receptor t cell therapy, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):549. doi: 10.1182/blood-2021-146060
   Google Scholar
• Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. JCO. 2021;39(15_suppl):8005. doi: 10.1200/JCO.2021.39.15_suppl.8005
   Web of Science ®Google Scholar
• San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023 Jul 27;389(4):335–347. doi: 10.1056/NEJMoa2303379
   PubMed Web of Science ®Google Scholar
• Manier S, San-Miguel J, Dhakal B, et al. Additional analysis of CARTITUDE-4: cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy. In: Presented at: 2023 International Myeloma Society Annual Meeting; Athens, Greece; 2023 Sep 27–30. Abstract OA–47.
   Google Scholar
• Sperling AS, Derman BA, Nikiforow S, et al. Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM). ASCO 2023 Abstract #8004. J Clin Oncol. 2023;41(16_suppl):8004. doi: 10.1200/JCO.2023.41.16_suppl.8004
   Google Scholar
• Ikegawa S, Prabhala RH, Sperling AS, et al. Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in < 2 days on the T-Charge platform. In: Presented at: International Myeloma Society 20th Annual Meeting and Exposition; Athens, Greece; 2023 Sep 27–30. OA–06.
   Google Scholar
• Du J, Fu W, Jiang H, et al. P869: Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting FASTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Hemasphere. 2023 Aug 8;7(Suppl):e84060bf. doi: 10.1097/01.HS9.0000970380.84060.bf
   Google Scholar
• Frigault MJ, Bishop MR, Rosenblatt J, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023 Mar 14;7(5):768–777. doi: 10.1182/bloodadvances.2022007210
   PubMed Web of Science ®Google Scholar
• Oliver-Caldés A, González-Calle V, CabañCabañAs V, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Lancet Oncol. 2023 Aug;24(8):913–924. doi: 10.1016/S1470-2045(23)00222-X
   PubMed Web of Science ®Google Scholar
• Costa JL, Kumar SK, Atrash S, et al. Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2022;140(Supplement 1):1360–1362. doi: 10.1182/blood-2022-160038
   Google Scholar
• Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023 Feb;29(2):422–429. doi: 10.1038/s41591-022-02182-7
   PubMedGoogle Scholar
• Zhang X, Zhang H, Lan H, et al. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol. 2023 Feb 20;14:1101495. doi: 10.3389/fimmu.2023.1101495
   PubMed Web of Science ®Google Scholar
• Manier S, Ingegnere T, Escure G, et al. Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev. 2022;54(17):100929. doi: 10.1016/j.blre.2022.100929
   PubMedGoogle Scholar
• Lin P, Reyes Silva FC, Lin P, et al. CD70 CAR NK cells in the treatment of multiple myeloma. Blood. 2023;142(Supplement 1):3463. doi: 10.1182/blood-2023-190612
   Google Scholar
• Fu J, Jiang L, Zhu Z, et al. Efficacy of human iPSC-Derived CAR-NK cells targeting multiple myeloma cells. Blood. 2023;142(Supplement 1):4802. doi: 10.1182/blood-2023-181613
   Google Scholar
• Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023 Apr 10;41(11):2087–2097. doi: 10.1200/JCO.22.01365
   PubMed Web of Science ®Google Scholar
• Sanoyan DA, Seipel K, Bacher U, et al. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients. BMC Cancer. 2023;23(1):345. doi: 10.1186/s12885-023-10824-3
   PubMed Web of Science ®Google Scholar
• Khanam R, Ashruf OS, Waqar SHB, et al. The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review. Antibodies (Basel). 2023 May 29;12(2):38. doi: 10.3390/antib12020038
   PubMedGoogle Scholar
• Hosny M, Verkleij CPM, van der Schans J, et al. Current state of the art and prospects of T cell-redirecting bispecific antibodies in multiple myeloma. J Clin Med. 2021 Oct 6;10(19):4593. doi: 10.3390/jcm10194593
   PubMed Web of Science ®Google Scholar
• Müller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther. 2007 Aug;9(4):319–326.
   PubMedGoogle Scholar
• U.S. Food & Drugs Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Media Release. 2022 Oct 26. Available from: https://www.fda.gov
   Google Scholar
• Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 Aug 21;398(10301):665–674. doi: 10.1016/S0140-6736(21)01338-6
   PubMed Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022 Aug 11;387(6):495–05. doi: 10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• Nooka AK, Moreau P, Usmani SZ, et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): updated efficacy and safety results from MajesTEC-1. JCO. 2022;40(16_suppl):8007–8007. doi: 10.1200/JCO.2022.40.16_suppl.8007
   Web of Science ®Google Scholar
• Johnson & Johnson. Pharmaceutical Pipeline. 2022. Available from: https://www.investor.jnj.com
   Google Scholar
• Cohen JC, Morillo D, Gatt ME, et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). 2023 ASCO Annual Meeting. Abstract #8002. JCO. 2023;41(16_suppl):8002–8002. doi: 10.1200/JCO.2023.41.16_suppl.8002
   Web of Science ®Google Scholar
• Rodriguez-Otero P, D’Souza A, Reece D, et al. Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results. HemaSphere. 2022Jun;6:89–90. doi: 10.1097/01.hs9.0000843644.02496.66
   Google Scholar
• Midha S, Leblebjian H, Laubach J, et al. Real-world experience of patients treated with teclistamab: a BCMA-directed bispecific T-cell engaging therapy for multiple myeloma. In: Presented at the 2023 International Myeloma Society Annual Meeting; Athens, Greece; 2023 Sep 27–30 p. Abstract OA–55.
   Google Scholar
• Sebag M, Raje NS, Bahlis NJ, et al. Elranatamab (PF-06863135), a B-Cell maturation antigen (BCMA) Targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood. 2021;138(Supplement 1):895. doi: 10.1182/blood-2021-150519
   Google Scholar
• Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA Targeted T-Cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022;140(Supplement 1):388–390. doi: 10.1182/blood-2022-166494
   PubMedGoogle Scholar
• Bahlis NJ, Tomasson MH, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma Naïve to B-Cell maturation antigen (BCMA)-Directed Therapies: Results from Cohort a of the MagnetisMM-3 Study. Blood. 2022;140(Supplement 1):391–393. doi: 10.1182/blood-2022-162440
   Google Scholar
• Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–2267. doi: 10.1038/s41591-023-02528-9
   PubMed Web of Science ®Google Scholar
• Grosicki S, Mellqvist UH, Pruchniewski L, et al. Elranatamab in combination with daratumumab for patients with relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 magnetismm-5 study safety lead-in cohort. ASH Abstract #1921. Blood. 2022;140(Suppl. 1):4407–4408. doi: 10.1182/blood-2022-162738
   Google Scholar
• Nooka AK, Lesokhin AM, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies. 2023 ASCO Annual Meeting. Abstract #8008. J Clin Oncol. 2023;41(suppl 16_suppl):8008. doi: 10.1200/JCO.2023.41.16_suppl.8008
   Web of Science ®Google Scholar
• Mateos MV, Grosicki S, Kim K, et al. MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma. 2023 ASCO Annual Meeting. TPS8066. J Clin Oncol. 2023;41(16_suppl):TPS8066. doi: 10.1200/JCO.2023.41.16_suppl.TPS8066
   Web of Science ®Google Scholar
• Grosicki S, Yeh SP, Huang SY, et al. MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM). 2023 ASCO Annual Meeting, Abstract #TPS8065. J Clin Oncol. 2023;41((suppl 16; abstr TPS8065). doi: 10.1200/JCO.2023.41.16_suppl.TPS8065
   Web of Science ®Google Scholar
• Grosicky S, Yeh SP, Huang SY, et al. PB2130: MagnetisMM-6: a phase 3 study of elranatamab + daratumumab + lenalidomide vs daratumumab + lenalidomide + dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma. Oral presentation at EHA2023. Hemasphere. 2023 Aug 8;7(Suppl):e039274c. doi: 10.1097/01.HS9.0000975284.03927.4c
   Google Scholar
• Bahlis NJ, Tomasson MH, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study. Blood. 2022 Nov15;140(Supplement 1):391–3. doi: 10.1182/blood-2022-162440
   Google Scholar
• Bumma N, Richter J, Brayer J, et al. Updated Safety and Efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: a phase 1/2 first-in-human study. Blood. 2022;140(Supplement 1):10140–10141. doi: 10.1182/blood-2022-159969
   Google Scholar
• Lee HC, Bumma N, Richter JR, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. 2023 ASCO Annual Meeting. Abstract #8006. JCO. 2023;41(suppl 16_suppl):8006. doi: 10.1200/JCO.2023.41.16_suppl.8006
   Web of Science ®Google Scholar
• Topp MS, Duell J, Zugmaier G, et al. Anti-B-Cell maturation antigen BiTE Molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020 Mar 10;38(8):775–783. doi: 10.1200/JCO.19.02657
   PubMed Web of Science ®Google Scholar
• Swan D, Murphy P, Glavey S, et al. Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety. Cancers (Basel). 2023 Mar 17;15(6):1819. doi: 10.3390/cancers15061819
   PubMed Web of Science ®Google Scholar
• Wong SW, Bar N, Victoria Mateos M, et al. P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from aphase 1 first-in-human clinical study. Hemasphere. 2023;7(S3):e1220745. doi: 10.1097/01.HS9.0000970436.12207.45
   Google Scholar
• Buelow B, Pham D, Choudry P, et al. T cell engagement without cytokine storm: A novel BCMA x CD3 antibody killing myeloma cells with minimal cytokine secretion. Blood. 2017;130:501. doi: 10.1182/BLOOD.V130.SUPPL_1.501.501
   PubMed Web of Science ®Google Scholar
• Buelow B, D’Souza A, Rodriguez C, et al. TNB383B. 0001: a multicenter, phase 1, open-label, dose-escalation and expansion study of TNB-383B, a bispecific antibody targeting BCMA in subjects with relapsed or refractory multiple myeloma. Blood. 2019;134(Supplement_1):1874. doi: 10.1182/blood-2019-123220
   Google Scholar
• Kumar S, D’Souza A, Shah N, et al. A phase 1 first-in-human study of tnb-383B, a BCMA x CD3 Bispecific T-Cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):900. doi: 10.1182/blood-2021-150757
   Google Scholar
• D’Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022 Nov 1;40(31):3576–3586. doi: 10.1200/JCO.22.01504
   PubMed Web of Science ®Google Scholar
• Plesner T, Harrison SJ, Quach H, et al. Phase i study of safety and pharmacokinetics of RO7297089, an anti-BCMA/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma. Clin Hematol Int. 2023 Mar;5(1):43–51. doi: 10.1007/s44228-022-00023-5
   PubMedGoogle Scholar
• Raab MS, Cohen YC, Schjesvold F, et al. Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. Leukemia. 2023 Jun;37(6):1349–1360. doi: 10.1038/s41375-023-01883-3
   PubMed Web of Science ®Google Scholar
• Delforge M, Patel KK, Eliason L, et al. Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2-4 prior regimens: updated results from the phase 3 KarMMA-3 trial. Blood. 2023;142(suppl 1):96. doi: 10.1182/blood-2023-179152
   Google Scholar
• Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 Jul 11;7(13):3069–3074. doi: 10.1182/bloodadvances.2022009435
   PubMed Web of Science ®Google Scholar
• Lancman G, Parsa K, Rodriguez C, et al. Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood. 2022;140(Suppl. Supplement 1):10073–10074. doi: 10.1182/blood-2022-163733
   Google Scholar
• Rodriguez-Otero P, Schinke CD, Chari A, et al. Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1. J Clin Oncol. 2023;41(16_suppl):8020–18020. doi: 10.1200/JCO.2023.41.16_suppl.8020
   Web of Science ®Google Scholar
• Frerichs KA, Verkleij CPM, Mateos MV, et al. Teclistamab impairs humoral immunity in heavily pretreated MM patients: importance of immunoglobulin supplementation. Blood Adv. 2023 Dec 5:2023011658. doi: 10.1182/bloodadvances.2023011658
   Web of Science ®Google Scholar
• Al Hadidi S, Szabo A, Esselmann J, et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 Apr;58(4):443–445. doi: 10.1038/s41409-022-01905-1
   PubMed Web of Science ®Google Scholar
• Touzeau C, Krishnan A, Moreau P, et al. Evaluating teclistamab in patients with relapsed/refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents. Hemasphere. 2022;6:85–86. doi: 10.1097/01.HS9.0000843628.63947.e4
   Google Scholar
• Madduri D, Berdeja JG, Usmani SZ, et al. CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma. Blood. 2020 Nov 5;136:22–25. doi: 10.1182/blood-2020-136307
   Web of Science ®Google Scholar
• Zhao Z, Chen Y, Francisco NM, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018 Jul;8(4):539–551. doi: 10.1016/j.apsb.2018.03.001
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Mohty M. Sequencing anti-BCMA therapies in myeloma. Blood. 2023;141(3):211–212. doi: 10.1182/blood.2022018157
   PubMed Web of Science ®Google Scholar
• Kourelis T, Bansal R, Berdeja J, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transplant Cell Ther. 2023;29(4):255–258. doi: 10.1016/j.jtct.2023.01.012
   PubMedGoogle Scholar